setrobuvir

Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.

Wikidata facts

Mass: 560.1200

Show 3 more facts

canonical SMILES: CS(=O)(=O)NC1=CC=C2C(=C1)S(=O)(=O)N=C(N2)C3=C(C4C5CCC(C5)C4N(C3=O)CC6=CC=C(C=C6)F)O
isomeric SMILES: CS(=O)(=O)NC1=CC=C2C(=C1)S(=O)(=O)N=C(N2)C3=C([C@@H]4[C@H]5CC[C@H](C5)[C@@H]4N(C3=O)CC6=CC=C(C=C6)F)O
chemical formula: C₂₅H₂₅FN₄O₆S₂

Sources (2)

via Wikidata · CC0

~1 min read

Article

1 sections

Contents

References

{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461749550 | Reference = | ImageFile = Setrobuvir.svg | ImageClass = skin-invert-image | ImageSize = 200px | ImageAlt = | PIN = N-(3-{(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide | OtherNames = ANA-598; ANA598

|Section1=